Omnio Raises €2.9M for Chronic Wound Therapy

Swedish biotech firm Omnio has successfully closed an oversubscribed funding round, bringing in €2.9 million. This capital infusion, primarily from its existing investor base and shareholders, is earmarked to propel its innovative plasminogen-based therapeutic candidate toward crucial clinical evaluation for chronic, difficult-to-heal wounds. The company, headquartered in Umeå, is making significant strides in addressing a persistent challenge within the healthcare sector.

This latest financial milestone follows a substantial €4.3 million financing secured in the spring of 2025. That earlier investment was instrumental in establishing the necessary Good Manufacturing Practice (GMP) compliant production processes, a critical prerequisite for advancing any therapeutic into human trials. The consistent backing from its current stakeholders underscores a strong belief in Omnio's scientific approach and market potential.

The global market for advanced wound care is experiencing robust growth, driven by an aging population, increasing prevalence of chronic diseases like diabetes, and a rising demand for more effective treatment modalities. Estimates suggest the advanced wound care market could reach tens of billions of dollars in the coming years, highlighting the significant unmet need Omnio aims to address. Current treatments often struggle with efficacy for complex, non-healing wounds, leading to prolonged patient suffering and substantial healthcare costs.

Omnio's therapeutic strategy centers on leveraging plasminogen, a naturally occurring protein involved in tissue remodeling and wound healing. By developing a targeted therapy based on this protein, the company seeks to reactivate the body's own healing mechanisms in chronic wounds that have stalled in their recovery process. This biological approach contrasts with many conventional treatments that focus on debridement or barrier functions.

The successful completion of this funding round positions Omnio to navigate the complex and capital-intensive journey of clinical development. The funds will support the preclinical activities and the initial phases of human trials, which are essential for demonstrating the safety and efficacy of their plasminogen-based therapy. The company's progress is being closely watched by investors and clinicians alike, given the potential impact on patient outcomes and the healthcare economy.

The consistent financial support from existing investors and shareholders is a testament to the company's trajectory and the perceived value of its proprietary technology. This confidence is vital as Omnio moves into the critical stages of validating its therapeutic candidate in a highly regulated industry. The company's focus on a specific, high-need area within regenerative medicine suggests a strategic approach to market entry.

As Omnio advances its plasminogen therapy, the broader medical community will be keenly observing the clinical data. Positive results could pave the way for a new class of treatments for chronic wounds, potentially reducing amputation rates, improving quality of life for millions, and offering significant cost savings to healthcare systems worldwide. The company's ability to attract further investment will likely hinge on the successful demonstration of therapeutic benefit in upcoming trials.